MedTrace Logo

Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years

NCT02102698 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-22

Study results available
· View outcomes & findings →

Summary

Tourette's Syndrome is a neurological disease characterized by motor and vocal tics. It has been hypothesized that abnormal interactions of dopamine with its receptors may cause the tics. The purpose of this study is to test the hypothesis that a drug (ecopipam) that selectively blocks dopamine D1/D5 receptors can reduce the frequency and severity of the tics.

Conditions

  • Tourette's Syndrome

Interventions

DRUG

Ecopipam

Ecopipam is a selective antagonist of the dopamine D1 receptor family.

Sponsors & Collaborators

  • Psyadon Pharma

    collaborator INDUSTRY

  • Emalex Biosciences Inc.

    lead INDUSTRY

Principal Investigators

  • Donald Gilbert, MD · Children's Hospital Medical Center, Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
7 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-19
Primary Completion
2019-12-31
Completion
2019-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02102698 on ClinicalTrials.gov